References
- Consortium on Safe Labor, Hibbard JU, Wilkins I, et al. Respiratory morbidity in late preterm births. JAMA. 2010;304(4):419–425.
- Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med. 2016;374(14):1311–1320.
- Saccone G, Berghella V. Antenatal corticosteroids for maturity of term or near term fetuses: systematic review and meta-analysis of randomized controlled trials. BMJ. 2016;355:i5044.
- American College of Obstetricians and Gynecologists. Committee Opinion No. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2017;130(2):e102–e109.
- National Institute for Health and Care Excellence. Preterm labour and birth 2015. Available from: https://www.nice.org.uk/guidance/ng25/chapter/Recommendations#maternal-corticosteroids.
- Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness – the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second Panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
- Martin JA, Hamilton BE, Osterman MJ, et al. Births: final data for 2015. Natl Vital Stat Rep. 2017;66(1):1.
- Lexicomp Online. Pediatric & neonatal Lexi-Drugs Hudson. Ohio: Lexi-Comp, Inc. Available from: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/5004822?hl=718330#. [Accessed: 29 November 2017].
- Agency for Health Care Research and Quality. HCUPnet; 2017. Available from: https://hcupnet.ahrq.gov. [Accessed: 22 November 2017]/#setup.
- United States Department of Labor Bureau of Labor Statistics. Consumer price Indices 2017. Available from: https://www.bls.gov. [Accessed: 27 November 2017]/.
- Carroll AE, Downs SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr. 2009;155(1):21–5, 25.e1.
- Bastek JA, Langmuir H, Kondapalli LA, et al. Antenatal corticosteroids for late-preterm infants: a decision-analytic and economic analysis. ISRN Obstet Gynecol. 2012;2012:491595.
- Roberts D, Brown J, Medley N, et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3:CD004454.
- Kotecha SJ, Dunstan FD, Kotecha S. Long term respiratory outcomes of late preterm-born infants. Semin Fetal Neonat Med. 2012;17(2):77–81.
- Collaco JM, McGrath-Morrow SA. Respiratory phenotypes for preterm infants, children, and adults: bronchopulmonary dysplasia and more. Ann Am Thorac Soc. 2018;15(5):530–538.
- Pike KC, Lucas JS. Respiratory consequences of late preterm birth. Paediatr Respir Rev. 2015;16(3):182–188.
- Kerstjens JM, Bocca-Tjeertes IF, de Winter AF, et al. Neonatal morbidities and developmental delay in moderately preterm-born children. Pediatrics. 2012;130(2):e265–e272.
- Gyamfi-Bannerman C. Antenatal late preterm steroids: a cost analysis. Am J Obstet Gynecol. 2018;218(1):S14.
- Porto AM, Coutinho IC, Correia JB, et al. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ. 2011;342:d1696.
- Balci O, Ozdemir S, Mahmoud AS, et al. The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecol Obstet Invest. 2010;70(2):95–99.
- Rawat M, Chandrasekharan P, Turkovich S, et al. Oral dextrose gel reduces the need for intravenous dextrose therapy in neonatal hypoglycemia. Biomed Hub. 2016;1(3).
- Petrou S, Khan K. Economic costs associated with moderate and late preterm birth: primary and secondary evidence. Semin Fetal Neonat Med. 2012;17(3):170–178.
- Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161–172.
- Thompson-Branch A, Havranek T. Neonatal hypoglycemia. Pediatr Rev. 2017;38(4):147–157.
- McKinlay CJD, Alsweiler JM, Anstice NS, et al. Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years. JAMA Pediatr. 2017;171(10):972–983.
- McKinlay CJ, Alsweiler JM, Ansell JM, et al. Neonatal glycemia and neurodevelopmental outcomes at 2 years. N Engl J Med. 2015;373(16):1507–1518.
- Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. BMJ. 1988;297(6659):1304–1308.
- Chatroux LR, Savitsky LM, Zwerling B, et al. Standardizing the response to Category II tracings during induction with oxytocin: a cost-effectiveness analysis. Am J Perinatol. 2017;34(12):1255–1263.
- McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. Obstet Gynecol. 2008;111(1):35–41.
- Teune MJ, Bakhuizen S, Gyamfi Bannerman C, et al. A systematic review of severe morbidity in infants born late preterm. Am J Obstet Gynecol. 2011;205(4):374.e1–374.e9.
- Melamed N, Klinger G, Tenenbaum-Gavish K, et al. Short-term neonatal outcome in low-risk, spontaneous, singleton, late preterm deliveries. Obstet Gynecol. 2009;114(2 Pt 1):253–260.
- Kaempf JW, Suresh G. Antenatal corticosteroids for the late preterm infant and agnotology. J Perinatol. 2017;37(12):1265–1267.
- Kamath-Rayne BD, Rozance PJ, Goldenberg RL, et al. Antenatal corticosteroids beyond 34 weeks gestation: What do we do now? Am J Obstet Gynecol. 2016;215(4):423–430.
- Jobe AH, Goldenberg RL. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Am J Obstet Gynecol. 2018;219(1):62–74.